Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Financial Advisor
on its pending ~$20 billion
merger with
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
December 23, 2022
Closed
Advised BMS on its investment from Eurazeo
Enterprise Value of £1,750
December 22, 2022
Closed
Advised ABC Technologies on its acquisition of WMG Technologies
$165
December 21, 2022
Closed
Advised IsoPlexis on its sale to Berkeley Lights
~$58
December 15, 2022
Closed
Advised Hillenbrand on its divestiture of its Batesville business to LongRange Capital
$762
December 13, 2022
Closed
Advised ODATA on its sale to Aligned Data Centers
N/A
December 13, 2022
Closed
Advised Crown Holdings on its defense and cooperation agreement with Icahn Enterprises
N/A
December 13, 2022
Closed
Advised Takeda on its acquisition of Nimbus Therapeutics’ TYK2 Inhibitor
Up to $6,000
December 8, 2022
Closed
Advised Keurig Dr Pepper on its strategic partnership and investment in Nutrabolt
$863
December 7, 2022
Closed
Advised Ontario Teachers’ Pension Plan Board, IFM and British Columbia Investment on its sale of GCT USA to CMA CGM
N/A
December 7, 2022
Closed
Advised IBM on its acquisition of Octo
N/A
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.